Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (691)	6/23/2003 2:07:34 PM
From: Icebrg	Read Replies (1) \| Respond to of 2240

Wilder I fully agree with you. You cannot trust these guys. The only reason to hold Medarex is MDX-010. DD notwithstanding. As for the IL-15 "collaboration". That's the way it is done in the industry. The smaller party will always try to give the impression that the deal is much more important than it really is. How many "strategic" collaborations have we not heard about over the years. Xoma did exactly the same thing the other day with one of the projects Millennium dumped on them with an opt-in back clause: "BERKELEY, CA — June 19, 2003— XOMA Ltd. (Nasdaq: XOMA), announced today the initiation of a phase I clinical trial of MLN2201 (formerly known as MLN01), a humanized monoclonal antibody being developed for conditions related to inflammation of the heart and blood vessels. MLN2201 is one of two products currently under development as part of an ongoing collaboration with Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM)." Dr. Garren wrote some friendly word about Medarex today by the way. I will post that to the HuMab board as he also mentioned ABGX and CAT. Erik